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ABSTRACT

ARTICLE HISTORY

Introduction: Chagas disease, caused by infection with the parasite Trypanosoma cruzi, represents a huge
public health problem in the Americas, where millions of people are affected. Despite the availability of
two drugs against the infection (benznidazole and nifurtimox), multiple factors impede their effective
usage: (1) gaps in patient and healthcare provider awareness; (2) lack of access to diagnosis; (3) drug
toxicity and absence of treatment algorithms to address adverse effects; (4) failures in drug supply and
distribution; and (5) inconsistent drug efficacy against the symptomatic chronic stage.
Areas covered: We review new approaches and technologies to enhance access to diagnosis and treatment to reduce the disease burden. We also provide an updated picture of recently published and ongoing
anti-T. cruzi drug clinical trials. Although there has been progress improving the research and development
(R&D) landscape, it is unclear whether any new treatments will emerge soon. Literature search methodologies included multiple queries to public databases and the use of own-built libraries.
Expert opinion: Besides R&D, there is a major need to continue awareness and advocacy efforts by
patient associations, local and national governments, and international agencies. Overall, health systems strengthening is essential to ensure vector control commitments, as well as patient access to
diagnosis and treatment.
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1. Introduction
Chagas disease, or American trypanosomiasis, is caused by the
protozoan parasite Trypanosoma cruzi (T. cruzi) and remains
one of the most deadly and intractable neglected tropical
diseases (NTDs) in the Western Hemisphere [1]. Updated information from the Global Burden of Disease Study (GBD) 2016
indicates that 7,100 people die from Chagas disease annually,
roughly the same number of Chagas disease-related deaths
that occurred a decade previously [2]. However, these numbers may represent highly conservative estimates with further
findings that as many as 200,000 people living with T. cruzi
infection may die over the next five years [3]. The GBD 2016
also finds that 7.2 million now live with Chagas disease, while
180,000 new T. cruzi infections occur annually [4].
Beyond its horrific disease burden and contribution to
infectious disease mortality, there is a profoundly disturbing
social impact dimension to Chagas disease related to its
importance as a health disparity. Today, tens of thousands of
people face a death sentence from their T. cruzi infection due
to Chagasic cardiomyopathy, which could be prevented by
timely access to diagnosis and anti-parasitic treatment with
one of two nitroheterocyclic drugs – benznidazole (BNZ) and
nifurtimox (NFX). Fueling a growing outrage from the global
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health community is the finding that approximately 90% of
the people infected with T. cruzi now live in Latin America’s
three wealthiest economies: Argentina, Brazil, and Mexico. In
the United States of America (USA), the richest country of the
continent and main destiny of those looking for a better
future, there are at least 200,000 immigrants from Latin
America living with Chagas disease with limited or no access
to treatment [5,6]. Furthermore, in Europe, there are around
120,000 immigrants from Latin America living with Chagas
diseases with a disparity of situations regarding access to
care and treatment [7,8].
The overwhelming majority of Chagas disease sufferers are
unable to gain access to diagnosis and treatment, not only
because they are poor, but also because governmental leaders
are either uninformed or uninterested. For example, it is noteworthy that the registration of BNZ for the treatment of
pediatric Chagas disease in the USA has not been approved
until very recently [9]. Documenting such assertions is not
easy and seeking solutions to diagnosis and treatment access
are not straightforward endeavors. In Mexico, for example,
there are almost one million people living with Chagas disease, although even that number may represent a profound
underestimate [10]. Yet, only 3,013 T. cruzi infection cases were
registered nationally between the years 2007 and 2011, less
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Chagas disease is a neglected disease caused by the parasite
Trypanosoma cruzi (T. cruzi) that affects millions of people in the
Americas. Traditionally stigmatizing, hidden by society and ignored
by governments, thanks to researchers, patients’ associations and
several other actors who have raised awareness and promoted education on the disease, there has been a shift towards improved
diagnosis, treatment, and control in recent decades.
There are highly sensitive and specific diagnostics for the acute and
the chronic stages of the infection. However, they are not widely
implemented in areas distant from reference laboratories due to
logistical issues and the lack of equipped facilities and trained personnel. Thus, more practical algorithms should be used to provide
point-of-care diagnostics.
Two drugs are available to treat the infection: benznidazole and
nifurtimox. Both are highly efficacious in newborns, but access to
treatment generally occurs at the chronic stage when symptomatology arises. Due to their frequent adverse side effects, pharmacovigilance programs to report drugs toxicities and a better management
of these in primary care establishments must be implemented to
ensure tighter adherence to medication.
Stronger involvement of public health institutions and authorities is
fundamental to progress in the disease control and its adequate
management. The establishment of counter-reference circuits integrated in national health services plans will be fundamental to
catalyze and scale up the attention and care of Chagas disease
patients in endemic and non-endemic settings.
Some regions have made great progresses in the control of vectorrelated transmission, but there are yet many where vector transmission is active. Increased cooperation between vector control programs and medical programs must be put on place to maximize
their impact in public health.
The role of patients’ associations must remain active and press on
other stakeholders so as to keep up Chagas disease visibility. Patients
´ organizations are at the frontline to demand attention from the
responsible authorities, ensure adequate medical care, and ask for
returns on investment from R&D.
In line with the disease awareness shift, the clinical research landscape has also changed for the better. There are several clinical
studies ongoing and their results are expected to improve diagnosis
and treatment policies.

than 1% of the actual number of people affected with the
disease [11]. A similar situation has been documented for the
USA [12] and also likely holds true across the Americas. We are
facing a situation where less than 1% of Chagas disease
patients have access to timely and appropriate diagnosis and
treatment [13,14].
Limiting access to essential medicines also has important
implications for new research and development (R&D) related
to therapeutic interventions. An exciting development on this
front is a new orally bioavailable nitroheterocyclic drug, fexinidazole, which is also effective against human African trypanosomiasis [15]. Additional drugs are also under development,
as well as there are Chagas disease vaccine (immunotherapeutic) candidates at pre-clinical stage [16]. In this respect, the
Texas Children’s Hospital Center for Vaccine Development,
a Product Development Partnership, is exploring an approach
that links therapeutic vaccination to pharmacotherapy [17].
However, any R&D successes must still face a formidable
gauntlet of truncated and mostly failed global access mechanisms. Similar forces are a barrier for access to new and innovative diagnostics [18].
Here we report on some of the major hurdles that currently
block access to the diagnosis and treatment of Chagas disease.

The problems include both scientific and socioeconomic
obstacles. This paper aims to elucidate the challenges they
pose and offer solutions.

2. The need of more practical and useful diagnostics
The poor access rate to Chagas disease therapeutic treatments
has its roots in the clinical nature of the disease itself and its
silent progression from the mostly asymptomatic acute stage
into the symptomatic chronic one [1]. Unfortunately, biomarkers of disease progression and standardized tools to determine
early response-to-treatment are yet unavailable, which greatly
complicates the prognosis and follow-up of patients [19].
Treatment administration, as in any other disease, needs to be
preceded by an adequate diagnosis. In the case of Chagas disease, when a clinical diagnosis is achieved, tissue disruptions
might already be too advanced for a chemotherapeutic intervention. Therefore, parasite detection must be sought before the
onset of overt symptomatology. In the acute infection stage, for
instance, upon congenital transmission of the parasite, parasitemia can be detected by direct microscopic observation [1].
However, this stage is short lasting and generally goes unnoticed
as there are often no symptoms at all. Approximately 30% of
these infected individuals will progress to evidence either
Chagasic cardiac or gastrointestinal disease. Those without clinical evidence of disease are said to be at the indeterminate stage,
whereas those with cardiac or gastrointestinal involvement are at
the determinate stage. The development of life-threatening
heart and/or digestive tract disruptions, which can be massive
and are called mega-syndromes, occurs in the long-lasting
chronic stage [1].
In both indeterminate and determinate Chagasic patients,
parasitemia is typically low and intermittent and the diagnosis
of the infection is made by means of indirect serological tests,
like enzyme-linked immunosorbent assays (ELISAs). This is
possible because high levels of parasite-specific immunoglobulins are produced upon T. cruzi infection (Figure 1). AntiT. cruzi type G immunoglobulins (IgGs) levels remain above
detection thresholds for many years, which is advantageous
for the serological diagnosis of the infection (Figure 1).
However, it turns out to be an inconvenience for a serologybased assessment of drug responses as it can take several
years for them to revert after the administration of treatment
[20]. Another issue to take into account in the diagnosis of the
infection is the wide genetic variability of the parasite, which
encompasses seven different genotypes grouped in Discrete
Typing Units (DTUs) [21]. A role of the parasite and host
genetics interplay has been suggested in relation to the sensibility to treatment of the distinct isolates, the pathological
signatures of the infection, and also in the anti-T. cruzi
immune response [21].
Some studies indicate that treatment interventions while
patients are in the indeterminate or early determinate stages
are critically important in order to prevent advanced disease
progression. In contrast, from the multi-centered BENEFIT trial
to evaluate BNZ efficacy it was found that patients with significant cardiac involvement progressed to advanced disease or
even died despite receiving specific anti-parasitic chemotherapy [3,22]. Currently, several classifications (for instance, AHCC,
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Figure 1. Timescale scheme of Chagas disease diagnosis and clinical status progression.

or Kuschnir´s modified) are in place to differentiate people with
early-stage (grades A-B or 0-I, respectively) versus late stage
(grades C-D or II-III, respectively) cardiac disease. Treatment of
patients with grades C-D or II-III was not encouraged previously
[1], a finding that appears to hold up in light of the recent
BENEFIT findings. These findings highlight the importance of
identifying both indeterminate patients with Chagas disease,
and possibly those with AHCC grades A-B or modified Kuschnir
grades 0-I too, since they might be successfully treated with
antiparasitic therapy if they were captured during populationwide screening campaigns [3]. In this way, it would be possible
to identify and treat chronically infected people before they
develop the symptomatology. Women at child-bearing age and
newborns should receive special attention because the treatment of mothers-to-be has been shown to largely reduce the
transmission rate [23–26], and the efficacy and tolerability of
current drugs by infected newborns is ~100% [1]. Moreover,
health economics studies evaluating Chagas disease surveillance in endemic and non-endemic settings indicate that widespread screening would be highly cost-effective [27–30]. In the
two disease scenarios studied, congenital (acute infection transmitted by chronically infected mothers) and indeterminate
(chronic asymptomatic stage), mass screening would save
health costs even at T. cruzi prevalence rates as low as 0.9%
or 0.05%, respectively (in fact estimated in a non-endemic
setting) [27,29].
Due to the very limited resources available for Chagas disease
management, and echoing the answers provided by Latin
American experts enquired by Picado et al. [18], efforts should
focus on making widely available point-of-care (PoC) tests to
diagnose congenital transmission and indeterminate chronic
patients [18]. However, if we want to enable generalized
Chagas disease diagnosis, there is an urgent need of more
practical diagnostic reagents and kits. Availability of easy-to-use
tools for the early assessment of treatment response would also

be highly valuable to promote and support the administration of
drugs against the infection. In this regards, there are some
biomarkers under research [19], but the evaluation of antiT. cruzi drug responses yet relies on the molecular amplification
of the parasite DNA from periphery blood obtained at distinct
times post-treatment. Unfortunately, its associated high costs
and technical requirements restrict its use to the context of wellfunded clinical trials [31].

2.1. Current Chagas disease diagnostics are impractical
in many regions
Regarding acute stage diagnostics, classical parasitological
methods (micromethod, hemoculture and xenodiagnoses)
are microscopy-based and rely on finding motile trypomastigotes in blood, thus they provide both low sensitivity and
specificity. Due to their poor performance, current algorithm
to diagnose congenital transmission involves two micromethods (at birth and at 1–2 months of age), and a further
confirmatory serological test once mother-derived IgGs have
waned at infant´s 8–12 months of age [32]. This has two major
drawbacks: a very high loss-to-treatment risk during pediatric
follow-up, and the reduction of drug efficacies the longer the
treatment is delayed [32]. Molecular amplification of T. cruzi
DNA, either by conventional polymerase chain reaction (PCR)
or by quantitative PCR (qPCR), has been shown to be more
sensitive and specific than classical parasitological techniques
[20]. Several laboratories have worked on the standardization
of the techniques so that their outcomes can be comparable
and implemented in clinic-based laboratories [20]. But molecular biology laboratories are expensive to mount and maintain, plus they require highly trained personnel to run them.
Therefore, despite its very good performance, molecular
detection is not generally used beyond regional or national
reference laboratories in endemic regions.
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In relation to the current chronic stage diagnostics, conventional serological tests (like ELISAs, indirect immunefluorescence or indirect hemagglutination assays) use serum
or plasma samples that entail venous extraction and blood
segregation by centrifugation, and they require a cold chain to
preserve the test reagents and the samples. Moreover, due to
the parasite´s antigenic diversity, the advice from the World
Health Organization (WHO) is to run two tests based on distinct antigenic sets and if their outcomes are not concurrent,
to employ a third technique [14]. This algorithm is costly, and
it requires equipment and resources that are usually not available in many laboratories of endemic regions. Furthermore,
the turnaround of results to the patient can take several
weeks, which involves a high risk of losing contact with the
patient for treatment.

2.2. What solutions could be implemented?
Fortunately, recent technological advancements are procuring
solutions to overcome the limitations mentioned above. We
will outline them separately considering first those for the
diagnosis of acute stage and then those for the diagnosis of
chronic Chagas disease.
In recent years, isothermal amplification methods that do
not require expensive equipment (such as thermocyclers or
gel visualization systems) and are easier to perform than PCR
assays have been developed for the molecular detection of
several NTDs [20]. At present, a prototype of Loop isothermal
AMPlification for T. cruzi-DNA (LAMP, Eiken Co., Japan) has
been tested with clinical samples and shown to have
a comparable performance to qPCR with blood-EDTA samples
[33]. Another LAMP test developed in house by Rivero et al.
[34] has also been shown to provide a comparable performance to current congenital transmission algorithm. LAMP is
based on a microbiological DNA polymerase that works at
a constant temperature of 65°C for 45 min with a set of 4 to
6 complex primer sequences to provide a highly sensitive and
specific amplification [35]. LAMP readout is qualitative, and the
results can be naked eye visualized in a short time given
a probe (e.g. calcein) is added to the reaction mix. If a digital
fluorimeter is used (e.g. Genie III), the reading can even be
semi-quantitative [33]. Notably, in Eiken´s T. cruzi-LAMP prototype, reagents are provided dried out in the lids of the reaction tubes which allow a ready-to-use format and a much
desirable room temperature storage [33]. More recently,
a Recombinase Polymerase Assay (RPA), which even requires
a lower amplification temperature and shorter amplification
time (40°C for 30 min) than LAMP, has been tested with
samples from naturally T. cruzi-infected dogs [36]. This RPA
has been coupled to a lateral flow strip for results reading, and
it was shown to provide excellent agreement with qPCR
results [36]. There are RPAs for the detection of other NTDs
[37,38], so it could also be very useful for Chagas disease
molecular diagnosis.
For the serological detection of T. cruzi-specific IgGs, rapid
diagnostic tests (RDTs) have been commercially developed
during the last two decades [39,40]. RDTs have clear advantages over conventional serology, as they can be stored at
room temperature, use a very small volume (5–25 µl) of finger

pricked whole blood, have an easy-to-run and read cassette
format, and provide a fast turnaround of results (less than 45
min) [40]. Several studies now support their implementation
as they have been extensively validated against conventional
tests [41–43]. For instance, an RDT is currently used for primary
screening of chronic Chagas disease in Bolivia [41].
Nonetheless, following the WHO guidelines of two-tests concordance, confirmation of that RDT primary result must yet be
made with a conventional serological test [14]. Such recommendations reduce the advantages of RDTs.
With the aim to fully exploit RDTs advantages and to
determine whether they can substitute conventional tests,
combinatory use of two RDTs has been proposed [41]. So far,
in a proof-of-concept study performed in the city of Sucre
(Bolivia), perfect agreement between the two RDTs used was
observed, and their sensitivity and specificity in comparison
with three conventional tests was 100% and 99.3%, respectively [41]. However, despite a promising performance in
Bolivia [41,43], RDTs have not worked so well when they
have been used in other geographical regions [44]. This
might be related to the high prevalence of the disease in
Bolivia, which may allow an easier detection, or to the fact
that the parasite strains used to produce the RDTs antigens
are those circulating in Bolivia. In any case, until more results
from different epidemiological areas are available, preliminary
geographical testing of the RDTs performance has been proposed before using them in a particular region [44]. In view of
the advantages they bring versus conventional tests, RDTs
implementation for Chagas disease surveillance should be
evaluated at larger scales.

3. Treatment of Chagas disease, and related issues
3.1. Drug regimens
Evidence about the benefits of Chagas disease treatment,
together with a growing understanding of the pathogenesis of
the disease, led to the paradigm that all T. cruzi-seropositive
patients should receive treatment with anti-T. cruzi drugs [45].
The recently published results of the SaMi-Trop cohort study
further reaffirm this statement as they demonstrate a beneficial
effect of BNZ in reducing the cardiac clinical progression of
chronic Chagas disease patients [46]. Therefore, antitrypanosomatid treatment should be provided to all T. cruziinfected people who do not present with advanced cardiac
complications (Kuschnir´s modified grades II-III), as by then clinical manifestations might not be improved [47]. Nonetheless,
access to treatment confronts important limitations. BNZ and
NFX, the only drugs available for T. cruzi infection, exhibit reduced
efficacy during the chronic stage of the disease, and require
a long period of administration which causes frequent unwanted
drug-related adverse reactions (ADRs) [48–50]. Furthermore, variable drug susceptibility has been already described among distinct T. cruzi strains [51]. In this context, there is an urgent need for
more efficacious and safer drugs or drugs´ regimens, in particular
for the treatment of the chronic stage of the infection.
One alternative is the reduction of the BNZ dose and/or
schedule in order to improve safety and adherence to treatment; an approach that is supported by clinical and
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experimental data. In a pilot study, Álvarez et al. [52] assessed
a new scheme of BNZ administration in a small cohort of
chronic Chagas disease patients treated with intermittent
doses of BNZ at 5 mg/kg/day every 5 days for a total of
60 days. The study showed a satisfactory safety profile, with
low rates of treatment suspension and treatment failure [52].
An experimental study using a mouse model of chronic T. cruzi
infection had demonstrated before the effectiveness of an
intermittent scheme of BNZ administered every 5 days for
40 days [53]. These findings support the intermittent administration of BNZ as a new dosage schedule, but further research
to confirm its efficacy by long-term assessment of larger
cohorts is needed. Another therapeutic option under investigation is the co-administration of an immunotherapeutic (vaccine) treatment and BNZ. In this regards, enhancement of
a T. cruzi-specific immune response has been shown to contribute to support the efficacy of reduced BNZ dosages in
a mouse model of acute T. cruzi infection [17].

3.2. Drug availability
Drug access is still a huge problem in some endemic areas
[13]. BNZ, generally the first line therapy for Chagas disease,
is part of the WHO List of Essential Medicines [54]. It was
produced for more than 40 years by Roche (Basilea,
Switzerland), which transferred its production rights to
Laboratório Farmacêutico de Pernambuco (LAFEPE),
a Brazilian public enterprise, at the end of the twentieth
century. Sadly, BNZ production and distribution by LAFEPE
failed to meet expectations in terms of meeting supply and
demand requirements and in 2011 an important shortage of
the drug occurred. It lasted 1.5 years and left thousands of
patients without treatment worldwide [13,55]. This fact led
to the development of a Private–Public Partnership in
Argentina involving Maprimed (for the synthesis of the
drug) and ELEA (for its development and production), to
promote equitable availability of BNZ [56]. Since 2012, this
Argentinian Partnership has worked to guarantee the availability of the drug, distributing BNZ to the countries in the
region [56]. NFX, which is mostly used as the second line
treatment option, is produced and donated by the pharmaceutical company Bayer and distributed through the PanAmerican Health Organization (PAHO) Strategic Fund [57].
Recently, a NFX produced by Gador has also been registered
in Argentina. Definitely, a regular, safe and accessible production of these two anti-parasitic drugs is necessary to
guarantee the treatment to diagnosed patients, and the
access to drugs has to be ensured in adequate quantity,
quality, location, and timing.
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which predicts hazard from future administration and warrants
prevention or specific treatment, or alteration of the dosage
regimen, or withdrawal of the product’ [58]. The most commonly observed ADRs related to BNZ are headache, dermatological manifestations, and gastrointestinal symptoms [49,50].
Concerning NFX, digestive symptoms are the most frequent
[48]. Nevertheless, with an adequate clinical management,
most of the patients are able to finish treatment in the advent
of ADRs [49]. Close medical follow-up, adequate monitoring of
ADRs and implementation of robust pharmacovigilance systems are essential factors to avoid patient abandonment and
achieve therapeutic success.
Although pharmacovigilance is crucial, it is still
a neglected area. Latin-American countries are making
important efforts to report ADRs, but these activities are
recent and need reinforcement [59,60]. Results of an unpublished study conducted by Cortes-Serra et al. in Bolivia during 2016 indicate that 35.4% of the total patients treated for
Chagas disease in 14 healthcare centers of the department
of Cochabamba suffered ADRs related to it. From all ADRs
classified as moderate or severe (25% of the total ADRs
registered), only about half of them (51.43%) were reported
to the Bolivian Pharmacovigilance system [61]. This data
illustrate the urgency of implementing policies to promote
training in pharmacovigilance to all healthcare professionals,
as well as strictly recommend the follow-up on drug monitoring and ADR reporting. Altogether, these features are
fundamental to achieve strong and consolidated ADR
reporting systems, which will improve patient safety, drug
efficacy and adherence to treatment.

4. Patients’ comprehensive care: reference and
counter-reference circuits
With less than 1% people treated [13,14], and an economic
burden of $7.19 billion per year and $188.8 billion per lifetime [62], Chagas disease remains neglected despite the
efforts performed by several institutions focused on the
development and research [13]. Migratory flows have changed the epidemiology of the disease that is now emerging
in some non-endemic countries [7]. During the last decades,
collaboration and knowledge transfer between institutions
from endemic (CEADES, Bolivia) and non-endemic countries
(ISGlobal, Spain) have been strategic to build attention models for the Chagas disease patient. Such models could be
scaled-up by national health systems in endemic and nonendemic countries in order to expand Chagas disease
healthcare to people living in areas with limited access to
health (e.g. rural areas in endemic countries) or to vulnerable populations (e.g. migrants in endemic and nonendemic countries).

3.3. Pharmacovigilance
A major limitation of current Chagas disease treatments is the
onset of Adverse Drug Reactions (ADRs), which may lead to
poor medication adherence, and cause thereby therapeutic
failure or ineffective treatment [48–50]. ADRs are defined as
‘an appreciably harmful or unpleasant reaction, resulting from
an intervention related to the use of a medicinal product,

4.1. The Platform for integral care of Chagas disease
patients
The work made by this Platform in recent years have produced
a quantitative and qualitative improvement in the healthcare
provided to Chagas disease patients in Bolivia, but this
improvement certainly needs to be strengthened. The
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experience gained with the Platform in the country has shown
that the implementation of specialized centers to manage
people at risk of having Chagas disease is highly effective,
both based on the percentage (and number) of people diagnosed with the infection, and amongst them, those who
received and completed treatment [63]. This vertical strategy
has been essential to design the attention model for patients
with Chagas, making the medical assistance to these people
look like a normalized and necessary action [63]. Nevertheless,
the sustainability of such model ultimately depends on continuously securing external funds, which greatly complicates
its expansion to larger geographical levels, like national coverage by the national health system (Figure 2).

4.2. Vertical-to-horizontal healthcare model transition
In order to have a higher impact in terms of diagnosis and
treatment coverage, as well as to ensure the sustainability for
the model of care of Chagas disease patients already installed,
it is mandatory to search for a comprehensive horizontal
strategy together with local higher level entities of the public
health system. In fact, based on WHO recommendations, the
strategy to include the Chagas disease attention roadmap as
part of the regular activities of all healthcare levels seems to
be the most appropriate approach [64].
Simplifying the vertical Chagas disease model of healthcare
to more realistic protocols established together with the
national health institutions has allowed the improvement of
healthcare access for people at risk of having the disease living
in remote areas of an endemic country [63]. Researchers at
ISGlobal (authors of this review) have yet unpublished data
which demonstrate that the health coverage, in terms of
patients diagnosed and treated in the selected area in which
the project has expanded its activity, was five times higher in
the three years following the horizontal comprehensive care
model than the number of people covered in the five previous
years with the vertical strategy (Pinazo et al., unpublished).
So far, the outcome of the vertical-to-horizontal healthcare
model transition highlight that it could be worthy to replicate
and/or adapt it to other regions or countries. The first step
would be to coordinate with local health authorities at different levels in order to design an appropriate strategy. For the

implementation of a healthcare model, the identification of
interested health workers is a key issue. Even if it is simplified,
a strategy to offer a comprehensive care for people at risk of
suffering from Chagas disease should include: (a) specific
training of health workers on the disease management; and
(b) a strategy to increase the demand of the civil society,
based on promotional and educational community activities.
In this regard, the establishment of referral and counterreferral circuits tailored to each epidemiological and logistic
situation is highly relevant, even in nearby areas.

4.3. Requirements for the expansion of the Chagas
disease healthcare model
Referral and counter-referral circuits, in terms of patients and
samples for diagnosis or any other test, should include different healthcare levels to cover different levels of complexity in terms of care. The specialized centers in which the
model of care has been rehearsed in Bolivia are key towards
organizing these circuits, as well as to act as reference centers for complicated cases and to accompany the doubts and
the continuing education of health professionals from primary care centers. This is particularly important in health
systems where there is often a fast renewal of healthcare
personnel. Another crucial point to make sustainable
a comprehensive horizontal strategy against Chagas disease
is to promote an inter-sectorial collaboration with vector
control authorities (promoters of house refurbishment, disinfestation programs,…) and the educational system itself.
Vector control interventions are fundamental to halt vectordependent transmission and enable an enhanced drug control of the cases. Whereas educational activities to widen the
population knowledge and perception of the disease, its
impact, and treatment possibilities are crucial, because producing changes in beliefs, attitudes, and behaviors on both
medical staff and patients still stand as one of the major
challenges that must be faced when dealing with Chagas
disease. All these measures have a role to play in order to
consolidate the successful management of the disease.
On the other hand, lessons learned from the primary
healthcare network have shown that it is mandatory to ensure
the supervision of the circuits and surveillance the quality of

Figure 2. Comparison of the respective characteristics and requirements (in boxes) of the vertical and horizontal strategies to implement Chagas disease healthcare.
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the process, tasks that should be carried out by the national
health system responsible personnel in duty. Political engagement at this point is mandatory to contribute to a better
control of the disease as a public health problem. In relation
to this, it is important to respect the capability of local health
institutions, agreeing with them timelines and a progressive
increase of the number of people diagnosed and treated in
order to answer adequately to people’s demands. It must be
noted that external factors like the poor availability of drugs
for Chagas disease treatment have a sourly negative impact
on any planning.

5. Patients treatment in relationship with vector
control
Access to diagnosis and treatment of Chagas disease in areas
with active vector transmission requires a multidisciplinary
approach. It involves the participation of players from several
areas of expertise and different government sectors, from
vector control authorities to health service providers, including
primary healthcare [65].
Following the advice from the PAHO, intergovernmental
regional initiatives were created at the end of the twentieth
century and beginning of the twenty-first century to establish
supranational levels of action to bolster and monitor the
implementation of activities to prevent, control, diagnose
and treat Chagas disease in Latin America. These initiatives
were started by Southern Cone countries in 1991, and then
followed by Andean countries and Central American countries
in 1997 and Amazonian countries in 2004 [66,67]. Despite
these efforts, it is evident that in the region there was, and
still is, a breach between the programs for vector control and
the areas that are responsible for providing universal health
care (including diagnosis and etiological treatment) [68].
It is important to consider that although policies related to
the primary prevention of Chagas disease are defined at the
national level, primary healthcare attention for the patient is
the responsibility of the provincial/departmental or municipal/
local entities [69]. Often times, these final effectors of national
policies have little or no relation/communication with the
national entity and are sometimes even unaware of the policies themselves. For example, suggestion of treatment of the
infection by T. cruzi for postpartum women and their newborns, and the mandatory treatment for women of childbearing age and children under the age of one with Chagas
disease that are in the national or supranational norms [32],
make no specific mention of which protocols need to be
applied with respect to vector surveillance in the houses of
those patients living in endemic areas with active vector
transmission. However, recent public health interventions
have shown that activities related to access to diagnosis or
treatment of the disease are usually implemented and promoted by those responsible for vector control programs [70].
Thus, without consideration of the need of appropriate structures and circuits (i.e. access to an adequate laboratory for
diagnosis or presence of anti-trypanosomal drugs), which are
not usually present in rural areas, one of the main actions
needed is to establish and/or strengthen the link between
vector control programs and the health system providers
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[70]. Thereafter, following a stepwise approach, another action
to accomplish would be to provide technical recommendations to establish criteria for categorizing the risk of vector
transmission status in an endemic area. With that information
available, it could be possible to explicitly detail under which
conditions Chagas disease diagnosis and treatment has to be
made mandatory in the area for the entire population or
segments of it (i.e. women at childbearing age, newborns).
Finally, a most desired third action would definitely be to
integrate the procedures for disease diagnosis and treatment
within the health system as a transversal program.
Nowadays there are already a few experiences that have
been able to coordinate vector control actions together with
diagnosis and treatment in a successful manner [71,72]. These
could serve as proof-of-concept strategies for integral interventions to build on, improve and replicate. As an example, the
experience of Fundación Mundo Sano, with direct and uninterrupted action in the field since 2002, is worth mentioning. Its
integral program includes vector control and sanitary improvement of rural houses in the Department of General Taboada
(Santiago del Estero, Argentina). In 2015, after 13 years of vector
surveillance and control, Mundo Sano was able to install two
doctors’ offices dedicated to the diagnosis and treatment of
Chagas disease together with local institutions, one in Añatuya
City and another one in Colonia Dora. Since then, they have
been struggling with the problems of having a mono-disease
health service in a community that did not demand treatment.
Despite the difficulties, after almost three years of implementation, the amount of people diagnosed and treated begun to
increase. The work from these two Chagas disease-specific
offices was integrated to the local hospital of Añatuya in
2018, thus reaching a higher amount of T. cruzi-infected individuals derived from obstetrics, gynecology and cardiology services in addition to those attending the offices from
spontaneous demand. In the same line, the Platform for the
Integral Care of Chagas disease Patients was settled in Bolivia in
2009. Initially, in the province of Cochabamba in the center of
the country, the Platform now works also in municipalities of
the provinces of Chuquisaca and Tarija [63]. Each experience,
proposal or pilot study must be evaluated objectively in order
to improve and multiply its impact, avoiding a future with
a new inequality: one were those affected by the disease will
have access to health depending on whether they live in an
endemic or non-endemic area.

6. The role of patients’ associations
Similarly to what happens with other NTDs programs to promote scaling up of healthcare interventions, strategies
towards the control of Chagas disease often confront with
structural weaknesses of the health systems in which they
aim to be integrated [73–76]. Therefore, more effective strategies to strengthen those health systems are required to ensure
a sustainable integration of the required health innovations
within them. Importantly, these strategies need to incorporate
the patients´ perspective in order to overcome key access
barriers [13,14,75]. Barriers that nowadays still hinder the
access to diagnosis and treatment, barriers impeding
a better health care.
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In recent years, several associations of Chagas disease
patients have emerged and joined in a Federation of
Associations whose purposes are: (i) to increase the visibility
of the disease at all levels as well as of its overwhelming
impact in the patients´ health status; and (ii) to promote
a more active role of the people affected by the disease in
the decision-making processes. But these associations face
many difficulties (dispersion of objectives, multiplicity of
voices with different requirements, little real mobilization in
many countries, and lack of resources) to achieve their objective of having an effective role in the health policies makings
of their countries.
The WHO global strategy on integral health services centered on people could be a way through which these associations can play an important practical role [77]. In fact one of
the goals of such program is to empower individuals, families,
and communities by including in it some well-known activities
led by patients such as community education, groups of
patients for mutual support, expert patients to engage and
help others, etc. [77]. In addition, this WHO program goes
beyond a single disease and has the virtue of encompassing
other actors with decisive roles in health systems performance,
like governmental policy-makers, municipalities, donors, and
providers.
Overall, the strategy is thus envisaged to allow the community and patients to actively participate in the decisionmaking process, together with other involved actors, in issues
regarding their health. By doing so, they also play a role on
the way the health system is organized, for instance ensuring
that community and primary healthcare are prioritized.
Therefore, patients associations should look after the implementation and compliance with this WHO strategy as it underlies the activities they are already taking on.

7. The R&D agenda: clinical trials for new drugs or
new strategies of treatment with current drugs
7.1. Results from recently completed trials
Upon the questioned efficacy of currently available therapies
(BNZ and NFX) against the chronic symptomatic stage of the
disease, clinical testing of new drugs and/or of new regimens
of BNZ and NFX is being pursued. Nonetheless, some major
obstacles are in the way to getting more adequate treatments, including the poor understanding of the infection

pathophysiology leading to the disease clinical progression,
and the lack of biomarkers to determine prognosis and cure
(see review by Pinazo et al. [19]). Particularly the latter hinders the follow-up of treated patients both in the daily clinic
and in clinical trials. At present, an absence of molecular
amplification of T. cruzi DNA from periphery blood is used
as surrogate of ‘treatment success’. But this approach is far
from optimal, especially at the chronic stage of the disease
when the parasitemia is low and intermittent. A negative
result obtained at a determined time point does not exclude
the possibility that a positive one will be obtained in the next
visit. A false-negative PCR, i.e. a negative PCR result (‘treatment success’ event) in the patient follow up is then less
informative than a positive determination, as this one will
indeed define a case of treatment failure.
Despite this limitation, several clinical trials have been
completed in the last years, and there are several more currently ongoing. This advance represents a major shift in the
research landscape of this historically forgotten NTD. The vast
majority of the performed trials have been Phase 2 randomized, multi-centric, double-blinded, efficacy and safety studies to evaluate oral dosage schemes for the treatment of
adult patients at indeterminate (asymptomatic) chronic stage
(see Table 1). Amongst them, CHAGASAZOL [78], STOP
CHAGAS [79] and E1224 [31] have evaluated for the first
time two triazole anti-fungal drugs (posaconazole (POS), and
the ravuconazole precursor E1224) for their anti-T. cruzi properties. In addition, the BENEFIT trial that evaluated the use of
BNZ for chronic stage treatment must also be highlighted as it
has been the largest Phase 3 Chagas disease trial performed
so far [47].
CHAGASAZOL and E1224 trials entailed a direct comparison
of POS and E1224 monotherapy at a high and a low dose to
a BNZ standard dosage group (5 mg/kg/day orally divided in
two daily doses for 60 days) [31,78]. In addition to monotherapy branches, STOP CHAGAS trial also included a study group
that received POS and BNZ as combined therapy [79]. In the
latter, treatment success was defined as a negative PCR value
at the day 180 follow-up visit [79], whereas parasitological
cure in CHAGASAZOL was determined by a negative PCR
result at 12 months follow-up [78]. The most stringent success
criteria was that of E1224 trial, which involved serial negative
PCR results (3 negative PCR results from 3 samples collected
over 7 days) at 65 days after the end of treatment and a further
negative PCR outcome at 12 months follow-up [31].

Table 1. List of the most relevant anti-T. cruzi clinical trials recently completed.

a

Name
CHAGASAZOL

NCT numbera
01162967

STOP CHAGAS

01377480

POS
POS-BNZ

120

E1224

01489228

E1224

231

BENEFIT

00123916

BNZ

Drug tested
POS

No. of patients
78

2854 (1896)c

Outcomeb
>80% (POS)
38.4% (BNZ)
>86% (POS)
14.3% (BNZ)
20% (POS+BNZ)
≥81% (E1224)
18% (BNZ)
44.6% (BNZ)d

Ref.
[78]
[79]
[31]
[47]

Clinical trial identification number (check it out at https://clinicaltrials.gov).
b
Study outcome shown as treatment failure measured by PCR; STOP CHAGAS entry also includes the failure rate in the POS+BNZ group.
c,d
Number in parenthesis stands for the number of patients with a PCR result at baseline of which 60.5% were positive. The outcome shown indicates the % of
initially PCR positive patients who were reported PCR positive again at two years.
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Although both POS and E1224 drugs showed good safety
and efficacy profiles at end of treatment in the three studies,
the suppressive effect on parasite clearance after 12 months
was much reduced in comparison to BNZ, which showed early
and sustained efficacy until 12 months of follow-up (Table 1).
Thus, neither POS nor E1224 were as good as BNZ and could
not substitute it as monotherapies.
In the BENEFIT trial, the treatment response was evaluated
in a sub-group of 1,896 subjects who had PCR results at
baseline (60.5% of them were positive) by PCR conversion at
the end of treatment, and at two and five years posttreatment [47]. Being a large multi-national study, the PCR
conversion rates varied geographically with Bolivia and
Argentina showing the best results, though it must be noticed
that such conversion did not correlate with clinical outcome
[47]. BENEFIT was devised to study whether BNZ administration to patients at the chronic stage of the disease would
widely have a clinical benefit for them [22,47]. Sadly, its conclusions, far from reassuring the role of BNZ turned out to be
a setback, as they suggested not-to treat patients with
advanced cardiac disease [47]. As it has been criticized elsewhere, this devastating conclusion drains from the fact that
many subjects with advanced cardiac involvement were
enrolled in the study [3,22]. Despite its negative outcome
due to a rather questionable study protocol design [22], the
BENEFIT trial involved ample cooperation between multiple
study sites opening the door to the performance of multinational Phase 3 Chagas disease trials in South America [47].

7.2. Ongoing clinical trials of anti-T. cruzi drugs
There are now some active and/or ongoing clinical trials.
Some test alternative BNZ dosing regimens to reduce exposure, improve tolerability and maintain efficacy as described
elsewhere [52], based also on the description of BNZ pharmacokinetics (PK) in Chagas disease adult patients [80]. In
others, the evaluation of NFX has gained prominence under
the promotion of Bayer, NFX producer. The use of fexinidazole, a nitroimidazole drug like BNZ that is being trialed for
human African trypanosomiasis and leishmaniasis (respectively caused by T. cruzi closely related Kinetoplastid parasites T. brucei gambiense and T. brucei rhodensiense, and by
Leishmania spp.), and the antiarrhythmic drug amiodarone
are also being clinically assessed for the first time against
T. cruzi based on their anti-parasitic capacities [81,82]. These
ongoing trials range from smaller Phase 1 to larger Phase 2
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and 3 efficacy studies. There are: (1) a Phase 1 safety, tolerability and bioavailability assessment of new NFX tablets and
another Phase 1 study to determine NFX PK in relation to
dietary habits; (2) a Phase 2 study to evaluate different BNZ
regimens (MULTIBENZ); (3) another Phase 2 study to evaluate
reduced and intermittent BNZ regimens, either given alone
or in combination with E1224 (BENDITA); (4) two more Phase
2 studies evaluating fexinidazole to, respectively, determine
dosing regimens and the minimal efficacious and safety dose;
(5) a Phase 2–3 trial to compare safety and efficacy of NFX
and BNZ (EQUITY); (6) a Phase 3 study to assess amiodarone,
a commonly used antiarrhythmic with selective anti-T. cruzi
properties, administered over 6 months to individuals with
mild-to-moderate Chagas cardiomyopathy (ATTACH); (7)
a Phase 3 study of a pediatric formulation of NFX (CHICO);
and (8) a very recently added Phase 3 study to evaluate
a short dose of BNZ in child-bearing age women (BETTY)
(Table 2).
All Phase 2 or above trials in Table 2 but CHICO involve
the evaluation of drugs in chronically infected adult patients,
and the measurement of treatment success will rely on molecular detection of the parasite DNA. In contrast, in CHICO,
designed to assess NFX performance in Chagas disease infant
population, the way to measure cure is seroconversion a year
after treatment because this is much easier to timely occur in
children than in adults and its readout is less ambiguous than
the PCR output. All these studies are currently in the recruiting stage, except FEXI NCT02498782 and CHICO which are
active but not recruiting, and BETTY that is not yet recruiting
(https://clinicaltrials.gov). Regarding the latter, the benefits of
treating T. cruzi-infected women before pregnancy have
been described by several smaller studies [23–26].
Hopefully, BETTY´s outcome will serve to enforce treatment
administration to all child-bearing age women as soon as
possible.

8. Conclusion
Increasing the awareness on the prevalence and health impact
of Chagas disease among patients, health practitioners, and
political health authorities may eventually translate to
enhance population-based diagnostic screening and treatment interventions. The tools needed to facilitate this activity
are being tested currently in the field and incorporate more
practical and point-of-care diagnostics, new drugs regimens,
and the standardization of daily clinical care routines. In

Table 2. List of currently ongoing clinical trials of anti-T. cruzi drugs.
Name
NCT numbera
03350295
03334838
MULTIBENZ 03191162
BENDITA
03378661
–
02498782
03587766
EQUITY
02369978
ATTACH
03193749
CHICO
02625974
BETTY
03672487
a

Drug tested
NFX
NFX
BNZ
BNZ and E1224
FEXI
NFX and BNZ
AMD
NFX
BNZ

Study type No. of patients (estimated)
Phase 1
48
Phase 1
36
Phase 2
240
Phase 2
210
Phase 2
140
45
Phase 2–3
500
Phase 3
200
Phase 3
330
Phase 3
600

Clinical trial identification number (check it out at https://clinicaltrials.gov).

Promoter
Bayer
Bayer
Hospital Vall d´Hebron (Spain)
DNDi
DNDi
Autonomous University of Bucaramanga (Colombia)
Fundación Cardioinfantil – Instituto de Cardiología de Bogotá (Colombia)
Bayer
Tulane University (USA)
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addition, efforts to obtain biomarkers of disease prognosis and
early assessment of treatment are also being pursued and will
probably yield results soon.
Upon failure of azoles, the majority of presently ongoing
Chagas disease clinical trials either evaluate alternative regimens of current drugs or other chemical entities distinct from
azoles (e.g. fexinidazole, amiodarone) with the aim to identify
dosages with lower toxicity and at least equal efficacies
compared to present chemotherapy with either benznidazole
or nifurtimox. There is certain optimism on that a new treatment for Chagas disease can be scheduled in the next few
years. Further complementing the new anti-parasitic drugs is
a new therapeutic biologic, a vaccine, now advancing to the
clinic. However, access to these new drugs and innovations
will require enhanced policies and advocacy activities. In
parallel, it will be essential to shape and disseminate pharmacovigilance protocols so that the performance of the drug
can be closely monitored, and patients´ and healthcare providers´ confidence on these therapies is promoted and
maintained.
The functional deployment of counter-reference circuits
fully integrated in the national health services will be
required to scale up the attention to Chagas disease
patients. In this regards, improved coordination between
vector control authorities and sanitary authorities needs
strengthening in those regions with active vector transmission of the infection. Widespread access to diagnosis and
treatment will not yield the desired outcome unless chances
to get re-infected are minimized or eliminated. This
approach also requires maintaining blood screening and
programs to stop congenital transmission. An improved
maternal diagnosis and treatment protocol would in itself
reduce congenital transmission.
Despite recently achieved advancements, Chagas disease
management and control is still a huge challenge. Therefore,
to succeed in this matter it will be paramount the continued
involvement of key actors, including patients associations,
health authorities at regional and national levels, governmental and non-governmental institutions, basic and clinical
researchers, and of course financial partners.

9. Expert opinion
A huge drawback in the management of Chagas disease has
traditionally been the lack of awareness of the disease and its
impact by both health professionals and the patients themselves, as well as by governmental institutions with the power
to dictate health policies. However, Chagas disease awareness
is gradually increasing, so that efforts to combat this
neglected tropical disease now need to shift in order to
address its often insidious onset and silent clinical progression.
These features currently complicate the access to timely diagnosis and treatment, which is also ballasted by the very limited
resources available for research and development of improved
treatment and disease prevention methodologies.
After so many years of neglecting Chagas disease, new
efforts at R&D have the potential for high returns on investment. However, the R&D needs for Chagas disease are pervasive and span requirements for both basic and applied

research, as well as new drugs, diagnostics, and vaccines.
With the ultimate goal of controlling the disease in endemic
and non-endemic regions, the consequences of widening our
understanding on Chagas disease and the pathogen that
causes it will have an impact on the lives of millions of people.
For instance, research on parasite–host interactions is needed
to fully comprehend the pathogenic processes that lead to the
life-threatening symptomatology characteristic of chronic
T. cruzi infections. Furthermore, considering that in the
absence of treatment ~30% of those chronically infected will
develop cardiac and/or digestive tract disruptions, studies on
both parasite and host genomics (and other omics) are
required to determine the key factors leading to the development of pathogenesis. Deeper understanding of the parasite
biology and of its interactions with the host is fundamental for
the discovery of safer drugs or vaccines. Another challenge is
the dearth of public policies and advocacy that so far has
mostly failed to attract requisite funding.
Currently, the most urgent needs include an expansion in
clinical studies to test an enlarged portfolio of new drugs,
together with improved biomarkers to monitor disease progress. There is also urgency for inexpensive and accessible
point-of-care diagnostics, especially for mass screenings as
well as for the early assessment of treatment responses.
Their availability will widen access to treatment because they
would introduce a more accurate picture of the disease epidemiology, as well as the ability to acknowledge cure upon
treatment.
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